Overactive Bladder - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 124 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Overactive Bladder - Pipeline Review, H2 2016, provides an overview of the Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline landscape.

Overactive bladder is a problem with bladder-storage function that causes a sudden urge to urinate. The urge may be difficult to stop, and overactive bladder may lead to the involuntary loss of urine (incontinence). Symptoms include feel a sudden urge to urinate that's difficult to control, experience urge incontinence and awaken two or more times in the night to urinate. Treatment includes change in life style and medications that relax the bladder can be effective for relieving symptoms of overactive bladder and reducing episodes of urge incontinence.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Overactive Bladder - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Overactive Bladder (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Overactive Bladder and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 7, 4, 4, 2, 10 and 1 respectively for Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively for Overactive Bladder.

Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Overactive Bladder (Genito Urinary System And Sex Hormones).
- The pipeline guide reviews pipeline therapeutics for Overactive Bladder (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Overactive Bladder (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Overactive Bladder (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Overactive Bladder (Genito Urinary System And Sex Hormones)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Overactive Bladder (Genito Urinary System And Sex Hormones).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Overactive Bladder Overview 10
Therapeutics Development 11
Pipeline Products for Overactive Bladder - Overview 11
Pipeline Products for Overactive Bladder - Comparative Analysis 12
Overactive Bladder - Therapeutics under Development by Companies 13
Overactive Bladder - Therapeutics under Investigation by Universities/Institutes 15
Overactive Bladder - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Overactive Bladder - Products under Development by Companies 19
Overactive Bladder - Products under Investigation by Universities/Institutes 21
Overactive Bladder - Companies Involved in Therapeutics Development 22
Addex Therapeutics Ltd 22
Allergan Plc 23
Asahi Kasei Pharma Corp. 24
Astellas Pharma Inc. 25
Dompe Farmaceutici S.p.A. 26
Dong-A Socio Holdings Co. Ltd. 27
FemmePharma Global Healthcare, Inc. 28
Hanmi Pharmaceuticals, Co. Ltd. 29
Hydra Biosciences, Inc. 30
Ion Channel Innovations, LLC 31
Ipsen S.A. 32
Jeil Pharmaceutical Co., Ltd. 33
Juniper Pharmaceuticals, Inc. 34
Lipella Pharmaceuticals, Inc. 35
Merck & Co., Inc. 36
Mezzion Pharma Co. Ltd. 37
Ono Pharmaceutical Co., Ltd. 38
Recordati S.p.A. 39
Sanofi 40
Seoul Pharma Co., Ltd. 41
Taris Biomedical LLC 42
TheraVida, Inc. 43
Toray Industries, Inc. 44
UroGen Pharmaceuticals, Ltd. 45
XuanZhu Pharma Co., Ltd. 46
Overactive Bladder - Therapeutics Assessment 47
Assessment by Monotherapy Products 47
Assessment by Combination Products 48
Assessment by Target 49
Assessment by Mechanism of Action 51
Assessment by Route of Administration 53
Assessment by Molecule Type 55
Drug Profiles 57
(mirabegron + solifenacin succinate) - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
(solifenacin succinate + tamsulosin hydrochloride) - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
abobotulinumtoxin A - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
ADX-71441 - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
DA-8010 - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
DFL-23448 - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
fadanafil - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
HC-067047 - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
HIP-1503 - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
mirabegron ER - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
onabotulinumtoxin A - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
onabotulinumtoxinA - Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
onabotulinumtoxinA SR - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
ONO-8577 - Drug Profile 83
Product Description 83
Mechanism Of Action 83
R&D Progress 83
oxybutynin chloride - Drug Profile 84
Product Description 84
Mechanism Of Action 84
R&D Progress 84
oxybutynin chloride - Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
Peptide to Antagonize PACAP Receptor for Pelvic Pain Syndrome and Overactive Bladder - Drug Profile 86
Product Description 86
Mechanism Of Action 86
R&D Progress 86
pVAX-hSlo - Drug Profile 87
Product Description 87
Mechanism Of Action 87
R&D Progress 87
REC-0438 - Drug Profile 88
Product Description 88
Mechanism Of Action 88
R&D Progress 88
SAR-244181 - Drug Profile 89
Product Description 89
Mechanism Of Action 89
R&D Progress 89
Small Molecule to Block TRPV1 for Overactive Bladder - Drug Profile 90
Product Description 90
Mechanism Of Action 90
R&D Progress 90
Small Molecules to Antagonize EP1 Receptor for Overactive Bladder - Drug Profile 91
Product Description 91
Mechanism Of Action 91
R&D Progress 91
solabegron hydrochloride - Drug Profile 92
Product Description 92
Mechanism Of Action 92
R&D Progress 92
solifenacin succinate - Drug Profile 94
Product Description 94
Mechanism Of Action 94
R&D Progress 94
SPO-1406 - Drug Profile 96
Product Description 96
Mechanism Of Action 96
R&D Progress 96
tacrolimus - Drug Profile 97
Product Description 97
Mechanism Of Action 97
R&D Progress 97
TAR-302 - Drug Profile 98
Product Description 98
Mechanism Of Action 98
R&D Progress 98
THVD-201 - Drug Profile 99
Product Description 99
Mechanism Of Action 99
R&D Progress 99
udenafil - Drug Profile 101
Product Description 101
Mechanism Of Action 101
R&D Progress 101
vibegron - Drug Profile 104
Product Description 104
Mechanism Of Action 104
R&D Progress 104
Overactive Bladder - Dormant Projects 105
Overactive Bladder - Discontinued Products 111
Overactive Bladder - Product Development Milestones 113
Featured News & Press Releases 113
Sep 27, 2016: Allergan to Present New Data at the American Urogynecologic Society Annual Meeting in Denver 113
May 03, 2016: Allergan Presents New Data on OnabotulinumtoxinA at the American Urological Association Meeting in San Diego 113
Mar 21, 2016: Juniper Pharmaceuticals Affirms Development Pathway for Oxybutynin Intra-vaginal Ring for Overactive Bladder in Women 114
Jan 11, 2016: Juniper Pharmaceuticals Submits Pre-IND Meeting Request for its First Intra-vaginal Ring Product 115
Oct 15, 2015: Allergan Announces New Long-Term OnabotulinumtoxinA Treatment Study Results at the American Urogynecologic Society Meeting 115
Jun 15, 2015: NeXeption Forms New Company Velicept Therapeutics Intends to Merge with AltheRx Pharmaceuticals to Advance Solabegron for the Treatment of Overactive Bladder 116
May 17, 2015: Mirabegron As Add-On Treatment To Solifenacin Therapy Demonstrated Superior Results To Solifenacin Monotherapy In BESIDE Trial 116
May 05, 2015: Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual Meeting 118
Dec 08, 2014: Lipella's Liposome Formulation of Botulinum Toxin (LP-09) Superior to Placebo for Overactive Bladder Symptoms in Double-Blind Trial 118
Apr 08, 2014: Positive Clinical Trial Results of Topical Botulinum Toxin for Overactive Bladder 118
Oct 17, 2013: AltheRx Pharmaceuticals is Granted U.S. Patent for Use of Solabegron in Combination with Antimuscarinics for the Treatment of Overactive Bladder 119
Sep 11, 2013: Allergan's BOTOX Receives Authorisation for the Treatment of Overactive Bladder in the UK 120
Jul 03, 2013: Impax Laboratories Confirms Patent Challenge Relating to Generic TOVIAZ 4 mg and 8 mg 121
May 21, 2013: Addex Validates Potential Efficacy Biomarker For Phase I Trial Of ADX71441 121
May 17, 2013: Astellas's Betmiga Obtains NICE Recommendation For Restricted Use In Treatment Of Overactive Bladder 122
Appendix 123
Methodology 123
Coverage 123
Secondary Research 123
Primary Research 123
Expert Panel Validation 123
Contact Us 123
Disclaimer 124

List of Tables

Number of Products under Development for Overactive Bladder, H2 2016 11
Number of Products under Development for Overactive Bladder - Comparative Analysis, H2 2016 12
Number of Products under Development by Companies, H2 2016 14
Number of Products under Investigation by Universities/Institutes, H2 2016 15
Comparative Analysis by Late Stage Development, H2 2016 16
Comparative Analysis by Clinical Stage Development, H2 2016 17
Comparative Analysis by Early Stage Development, H2 2016 18
Products under Development by Companies, H2 2016 19
Products under Development by Companies, H2 2016 (Contd..1) 20
Products under Investigation by Universities/Institutes, H2 2016 21
Overactive Bladder - Pipeline by Addex Therapeutics Ltd, H2 2016 22
Overactive Bladder - Pipeline by Allergan Plc, H2 2016 23
Overactive Bladder - Pipeline by Asahi Kasei Pharma Corp., H2 2016 24
Overactive Bladder - Pipeline by Astellas Pharma Inc., H2 2016 25
Overactive Bladder - Pipeline by Dompe Farmaceutici S.p.A., H2 2016 26
Overactive Bladder - Pipeline by Dong-A Socio Holdings Co. Ltd., H2 2016 27
Overactive Bladder - Pipeline by FemmePharma Global Healthcare, Inc., H2 2016 28
Overactive Bladder - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2016 29
Overactive Bladder - Pipeline by Hydra Biosciences, Inc., H2 2016 30
Overactive Bladder - Pipeline by Ion Channel Innovations, LLC, H2 2016 31
Overactive Bladder - Pipeline by Ipsen S.A., H2 2016 32
Overactive Bladder - Pipeline by Jeil Pharmaceutical Co., Ltd., H2 2016 33
Overactive Bladder - Pipeline by Juniper Pharmaceuticals, Inc., H2 2016 34
Overactive Bladder - Pipeline by Lipella Pharmaceuticals, Inc., H2 2016 35
Overactive Bladder - Pipeline by Merck & Co., Inc., H2 2016 36
Overactive Bladder - Pipeline by Mezzion Pharma Co. Ltd., H2 2016 37
Overactive Bladder - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 38
Overactive Bladder - Pipeline by Recordati S.p.A., H2 2016 39
Overactive Bladder - Pipeline by Sanofi, H2 2016 40
Overactive Bladder - Pipeline by Seoul Pharma Co., Ltd., H2 2016 41
Overactive Bladder - Pipeline by Taris Biomedical LLC, H2 2016 42
Overactive Bladder - Pipeline by TheraVida, Inc., H2 2016 43
Overactive Bladder - Pipeline by Toray Industries, Inc., H2 2016 44
Overactive Bladder - Pipeline by UroGen Pharmaceuticals, Ltd., H2 2016 45
Overactive Bladder - Pipeline by XuanZhu Pharma Co., Ltd., H2 2016 46
Assessment by Monotherapy Products, H2 2016 47
Assessment by Combination Products, H2 2016 48
Number of Products by Stage and Target, H2 2016 50
Number of Products by Stage and Mechanism of Action, H2 2016 52
Number of Products by Stage and Route of Administration, H2 2016 54
Number of Products by Stage and Molecule Type, H2 2016 56
Overactive Bladder - Dormant Projects, H2 2016 105
Overactive Bladder - Dormant Projects (Contd..1), H2 2016 106
Overactive Bladder - Dormant Projects (Contd..2), H2 2016 107
Overactive Bladder - Dormant Projects (Contd..3), H2 2016 108
Overactive Bladder - Dormant Projects (Contd..4), H2 2016 109
Overactive Bladder - Dormant Projects (Contd..5), H2 2016 110
Overactive Bladder - Discontinued Products, H2 2016 111
Overactive Bladder - Discontinued Products (Contd..1), H2 2016 112